Natixis Advisors LLC Purchases 213,937 Shares of Bruker Co. (NASDAQ:BRKR)

Natixis Advisors LLC increased its stake in shares of Bruker Co. (NASDAQ:BRKR) by 145.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 360,631 shares of the medical research company’s stock after purchasing an additional 213,937 shares during the quarter. Natixis Advisors LLC owned about 0.24% of Bruker worth $21,140,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of BRKR. True Wealth Design LLC grew its stake in shares of Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 510 shares during the last quarter. Eagle Bay Advisors LLC grew its stake in shares of Bruker by 2,324.1% during the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 674 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 248 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Bruker by 47.5% during the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock valued at $75,000 after purchasing an additional 412 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Bruker by 41.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company’s stock valued at $78,000 after purchasing an additional 390 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Trading Up 2.1 %

BRKR opened at $46.94 on Tuesday. The firm’s fifty day moving average is $53.38 and its two-hundred day moving average is $58.22. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The firm has a market cap of $7.12 billion, a PE ratio of 61.76, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker Co. has a twelve month low of $44.11 and a twelve month high of $94.86.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Equities research analysts anticipate that Bruker Co. will post 2.69 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.43%. Bruker’s payout ratio is 26.32%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BRKR. Bank of America increased their price target on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, December 13th. UBS Group assumed coverage on shares of Bruker in a report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price objective on the stock. Barclays cut their price objective on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Guggenheim restated a “buy” rating on shares of Bruker in a report on Monday, February 24th. Finally, Stifel Nicolaus cut their price objective on shares of Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a report on Friday, February 14th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Bruker presently has a consensus rating of “Moderate Buy” and a consensus target price of $70.50.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.